Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 209

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 209
---
 Neuropathy Market Size, Share and Trends 2025 to 2034, Precedence Research, Updated January 2025

| Moore Financial Consulting |

| MIRA Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 11 of 28 |

<div align='center'>Global DPN market size (USD Billion)</div>

Source: Precedence Research

The same Precedence Research states that the U.S. diabetic neuropathy market was valued at USD 1.28 billion in 2024 and is anticipated to reach approximately USD 2.62 billion by 2034, expanding at a compound annual growth rate (CAGR) of 7.42% during the forecast period from 2025 to 2034.

<div align='center'>US DPN market size (USD Billion)</div>

Source: Precedence Research

| Moore Financial Consulting |

| MIRA Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 12 of 28 |

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) is a clinical condition that represents an intermediate stage between normal age-related cognitive decline and dementia. It involves noticeable issues with memory, language, or judgment, but these changes are not severe enough to interfere with daily functioning or independent living.

Individuals with MCI are often aware of changes in their cognitive abilities, and these changes may also be observed by close family or friends. However, the impact typically does not disrupt routine activities.

While MCI increases the risk of developing Alzheimer’s disease or other forms of dementia, progression is not guaranteed. In some cases, symptoms remain stable or even improve over time.

MCI does not have a single, definitive cause. Instead, it results from a combination of factors that can affect brain function. Age is the most significant risk factor — MCI becomes more common as people get older, with an estimated 10% to 20% of adults over age 65 experiencing some form of it 3. In addition to aging, genetic predisposition and chronic health conditions such as diabetes, depression, and stroke can increase the likelihood of developing MCI. It’s also important to note that not all memory and thinking problems are permanent or progressive. Some are linked to treatable conditions, including:

| ■ | Adverse                  
 reactions to medications |

| ■ | Mental                                                  
 health challenges such as anxiety or emotional distress |

| ■ | Excessive   
 alcohol use |

|